Teva gives up on (former) partner's inhaler; Neos orally disintegrating tablet performs well in Phase III;

> Alexza Pharmaceuticals ($ALXA) is reacquiring the U.S. rights to its Adasuve inhalation powder from Teva ($TEVA). The company aims to find a new partner next year for the product to treat central nervous system conditions. It's delivered into the lungs via the Staccato hand-held inhaler. More

> Neos Therapeutics said its extended-release, orally disintegrating tablet for ADHD performed better than placebo in a Phase III trial. More

Suggested Articles

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.